MarketLens
Sign Up

What Do Recent Insider Sales at Spyre Therapeutics Signal

7 months ago
SHARE THIS ON:

What Do Recent Insider Sales at Spyre Therapeutics Signal

Exclusive Content for Pro Members

Pro members only. Upgrade to access this article, premium analysis, and stock recommendations.

SHARE THIS ON:

Related Articles

Category

You may also like

Stock News•2 months ago

Is SYRE a Buy Now as Clinical Catalysts Clash With Valuation Risk?

Spyre's investment case hinges on upcoming clinical readouts, as its broad pipeline and cash runway clash with an elevated valuation that leaves limited room for error.
Stock News•3 months ago

After a 96% 1-Year Run, This Director Sold 37,600 PHVS Shares for $1.3 Million. Is the Rally Over?

PHVS director sold 37,600 shares for $1.3 million after a 96% one-year rally. Insider selling at a rare-disease biotech may signal caution near current levels.
Stock News•4 months ago

MoonLake Immunotherapeutics' CFO Sells 39K Shares

MoonLake Immunotherapeutics' CFO sold 39,000 shares, a notable insider transaction at the clinical-stage Nanobody therapy company.

Breaking News

View All →

Top Headlines

View More →
Stock News•28 minutes ago

Q4 QQQ Roadmap: Navigating AI Turbulence & Market Headwinds

Stock News•59 minutes ago

Palantir: Why I Am Fine Paying 76x FWD Earnings

Stock News•1 hour ago

ALPHABET (GOOG) ALERT: Bragar Eagel & Squire, P.C Reminds Alphabet Inc. Investors a Class Action Lawsuit Has Been Filed and Urges Investors to Contact the Firm

Stock News•1 hour ago

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Alphabet Inc. of Class Action Lawsuit and Upcoming Deadlines – GOOG

Stock News•1 hour ago

GOOGL SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Alphabet Investors of Securities Class Action Lawsuit Deadline on November 30, 2026